iCAD Appoints Stacey Stevens as President and CEO

December 6, 2021 —iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Board of Directors appointedStacey Stevensas iCAD’s President and Chief Executive Officer (CEO), effective March 1, 2022. Stevens, who has served as the Company’s President since 2019, will also join the Company’s Board of Directors.Michael Klein他目前担任公司董事长兼首席执行官，并将继续担任iCAD董事会主席。

“On behalf of the entire Board of Directors, I would like to congratulate Ms. Stevens on this appointment. It has been a privilege to work closely with her for the past three years, as she brings a relentless focus on leading change and a proven track record of driving growth and innovation. I look forward to continued interaction in her new capacity as CEO,” said Klein, Chairman and CEO of iCAD, Inc. “We are currently at an important inflection point, with the recent launch of several first-in-kind technologies and the Company’s increasing focus on enterprise sales on the Detection side of the business, and with the expansion of Xoft in emerging applications, such as the treatment of brain tumors, on the Therapy side of the business. I am confident that with Ms. Stevens at the helm, iCAD and its technologies will continue to transform the landscape of cancer detection and therapy and accelerate the value we bring to all of our stakeholders.”

“I am honored to have the opportunity to lead the company at this exciting time in our growth,” said Stevens, President of iCAD, Inc. “iCAD’s technologies offer clinical performance superiority, workflow improvements, and a broad healthcare economic value proposition for both clinicians and patients. We are enhancing patient care and optimizing outcomes, which ultimately translates to improving, extending, and saving lives. I look forward to working with our talented and passionate team to advance the Company as we continue to evolve our business and technology, drive sustained market leadership, and create additional significant shareholder value.”

“The Board of Directors would also like to thank Mr. Klein for his significant contributions as CEO over the last three years,” said Nate Dalton, iCAD’s Lead Independent Director. “Under his leadership, the Company’s robust portfolio of cancer detection and therapy technologies has expanded, offering strong value propositions for clinicians, patients, and our shareholders. With iCAD now well positioned for future growth, we are confident that Ms. Stevens will strengthen iCAD’s position as an industry leader providing medical technologies that are improving the landscape of cancer detection and therapy, while delivering consistent returns to our shareholders.”

作为一名拥有20多年营销、战略和销售经验的成功高管，Stevens自2019年起担任iCAD总裁。在此之前，她于2017-2019年担任执行副总裁兼首席战略和商务官。她于2006年加入iCAD，担任营销和战略高级副总裁。在任职iCAD之前，她曾担任Philips Healthcare多个业务部门的多个商业领导职位。她持有the University of New Hampshire的政治科学学士学位，以及Boston University’s Questrom School of Business的工商管理硕士学位。史蒂文斯女士被任命为《今日CEO》的Businesswomen of the Year” in 2021.

For more information:www.icadmed.com